Table 1.
Subject Demographics and Characteristics
| All CPX Instances (n=68) |
Stage C (n=54) |
Stage D (n=14) |
p-Value | |
|---|---|---|---|---|
| Age, years | 54.53±12.68 | 54.81±12.88 | 53.43±12.28 | 0.53 |
| Female | 21 (31%) | 14 (26%) | 7 (50%) | |
| Height, cm | 172.4±9.14 | 172.67±9.34 | 171.4±8.57 | 0.59 |
| Weight, kg | 87.99±18.39 | 87.57±17.96 | 89.59±20.63 | 0.68 |
| BMI, kg/m2 | 29.53±5.26 | 29.27±4.85 | 30.51±6.73 | 0.37 |
| Ejection fraction,% | 27.25±10.64 | 26.21±9.29 | 31.29± 14.46 | 0.13 |
| III | 32 (57%) | 20 (45%) | 12 (100%) | |
| Orthopnea | 17 (27%) | 13 (27%) | 4 (27%) | 0.73 |
| Bilateral leg edema | 12 (20%) | 8 (18%) | 4 (27%) | 0.23 |
| Systolic blood pressure, mmHg | 105±15 | 105±14 | 102±19 | 0.41 |
| Diastolic blood pressure, mmHg | 68±10 | 68±9 | 68±15 | 0.85 |
| BNP, pg/mL | 568.4±722.5 (23*) | 368±514 (17*) | 1136.3±962.1 (6*) | 0.02 |
| NT-proBNP, pg/mL | 1635.3±1671.2 (31*) | 1783.4±1687.7 (25*) | 1018.5±1587.5 (6*) | 0.35 |
| Serum Creatinine, mg/dL | 1.40±1.43 (60*) | 1.49±1.61 (46*) | 1.13±0.43 (14*) | 0.38 |
| Loop Diuretics, Furosemide, mg/d | 83.7±93.4 (68%) | 64±71 (65%) | 146.4±128.1 (79%) | 0.01 |
| B-blockers, Bisoprolol, mg/d | 6.1±3.8 (94%) | 5.9±3.9 (93%) | 6.7±3.7 (100%) | 0.54 |
| ACE-Inhibitors, Lisinopril, mg/d | 18.6±15.5 (10%) | 18.6±15.5 (13%) | 0 (0%) | … |
| ARB, Losartan, mg/d | 54.8±30.4 (19%) | 61.1±30.9 (17%) | 40.6±27.7 (29%) | 0.28 |
| ARNI, Sacubitril-Valsartan, mg/d | 102.4±64.2 (58%) | 101.2±64.8 (61%) | 107.7±65.5 (50%) | 0.91 |
| MRA, Spironolactone, mg/d | 29.8±16.7 (85%) | 29.3±15.5 (81%) | 31.6±20.7 (100%) | 0.64 |
| Subsequent Events (OHT/VAD/Death)a | 11(16%) | 7 (13%) | 4 (29%) | 0.16 |
Values shown are mean ± SD or n (% of population) or mean ± SD (% of population) unless otherwise indicated. Statistical significance between stage C and D subjects in values, where applicable, was evaluated using an unpaired t test or a chi-square test.; NYHA, New York Heart Association; BNP, b-type natriuretic peptide; NT-proBNP, N-terminal pro b-type natriuretic peptide; pg/mL, picogram per milliliter; mg/dL, milligram per deciliter; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor blocker – neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist; mg/d, milligram per day; OHT, orthotopic heart transplantation; VAD: ventricular assisted device implantation.
Number of CPX test instances with available lab results.
Subsequent events were recorded up to 6-months after the completion of the study. In the cases where one CPX subject had multiple events (e.g. VAD, followed by transplant later), only the first occurring event was counted as subsequent events for a particular subject.